Molecular Diagnosis of Cystic Neoplasms of the Pancreas: a Review.
Intraductal papillary mucinous neoplasm
Mucinous cystic neoplasm
Pancreatic cystic neoplasm
Pancreatic pseudocyst
Serous cystadenoma
Solid pseudopapillary tumor of the pancreas
Journal
Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
ISSN: 1873-4626
Titre abrégé: J Gastrointest Surg
Pays: United States
ID NLM: 9706084
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
17
08
2019
accepted:
29
01
2020
pubmed:
5
3
2020
medline:
15
4
2021
entrez:
5
3
2020
Statut:
ppublish
Résumé
The prevalence of incidental pancreatic cystic neoplasms (PCNs) has increased dramatically with advancements in cross-sectional imaging. Diagnostic imaging is limited in differentiating between benign and malignant PCNs. The aim of this review is to provide an overview of biomarkers that can be used to distinguish PCNs. A review of the literature on molecular diagnosis of cystic neoplasms of the pancreas was performed. Pancreatic cysts can be categorized into inflammatory and non-inflammatory lesions. Inflammatory cysts include pancreatic pseudocysts. Noninflammatory lesions include both mucinous and non-mucinous lesions. Mucinous lesions include intraductal papillary mucinous neoplasm (IPMN) and mucinous cystic neoplasm. Non-mucinous lesions include serous cystadenoma and solid-pseudopapillary tumor of the pancreas. Imaging, cyst aspiration, and histologic findings, as well as carcinoembryonic antigen and amylase are commonly used to distinguish between cyst types. However, molecular techniques to detect differences in genetic mutations, protein expression, glycoproteomics, and metabolomic profiling are important developments in distinguishing between cyst types. Nomograms incorporating common clinical, laboratory, and imaging findings have been developed in a better effort to predict malignant IPMN. The incorporation of top molecular biomarker candidates to nomograms may improve the predictive ability of current models to more accurately diagnose malignant PCNs.
Sections du résumé
BACKGROUND
The prevalence of incidental pancreatic cystic neoplasms (PCNs) has increased dramatically with advancements in cross-sectional imaging. Diagnostic imaging is limited in differentiating between benign and malignant PCNs. The aim of this review is to provide an overview of biomarkers that can be used to distinguish PCNs.
METHODS
A review of the literature on molecular diagnosis of cystic neoplasms of the pancreas was performed.
RESULTS
Pancreatic cysts can be categorized into inflammatory and non-inflammatory lesions. Inflammatory cysts include pancreatic pseudocysts. Noninflammatory lesions include both mucinous and non-mucinous lesions. Mucinous lesions include intraductal papillary mucinous neoplasm (IPMN) and mucinous cystic neoplasm. Non-mucinous lesions include serous cystadenoma and solid-pseudopapillary tumor of the pancreas. Imaging, cyst aspiration, and histologic findings, as well as carcinoembryonic antigen and amylase are commonly used to distinguish between cyst types. However, molecular techniques to detect differences in genetic mutations, protein expression, glycoproteomics, and metabolomic profiling are important developments in distinguishing between cyst types.
DISCUSSION
Nomograms incorporating common clinical, laboratory, and imaging findings have been developed in a better effort to predict malignant IPMN. The incorporation of top molecular biomarker candidates to nomograms may improve the predictive ability of current models to more accurately diagnose malignant PCNs.
Identifiants
pubmed: 32128679
doi: 10.1007/s11605-020-04537-2
pii: 10.1007/s11605-020-04537-2
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1201-1214Références
Garcea G, Ong SL, Rajesh A, Neal CP, Pollard CA, Berry DP, et al. Cystic lesions of the pancreas. A diagnostic and management dilemma. Pancreatology. 2008;8:236–51.
pubmed: 18497542
Tanaka M, Fernández-del Castillo C, Adsay V, Chari S, Falconi M, Jang JY, et al. International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology. 2012;12:183–97.
pubmed: 22687371
Pancreas ESGoCTot. European evidence-based guidelines on pancreatic cystic neoplasms. Gut. 2018;67:789–804.
Tanaka M, Chari S, Adsay V, Fernandez-del Castillo C, Falconi M, Shimizu M, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology. 2006;6:17–32.
pubmed: 16327281
Tang RS, Weinberg B, Dawson DW, Reber H, Hines OJ, Tomlinson JS, et al. Evaluation of the guidelines for management of pancreatic branch-duct intraductal papillary mucinous neoplasm. Clin Gastroenterol Hepatol. 2008;6:815–9; quiz 719.
pubmed: 18602036
Pelaez-Luna M, Chari ST, Smyrk TC, Takahashi N, Clain JE, Levy MJ, et al. Do consensus indications for resection in branch duct intraductal papillary mucinous neoplasm predict malignancy? A study of 147 patients. Am J Gastroenterol. 2007;102:1759–64.
pubmed: 17686073
Ma GK, Goldberg DS, Thiruvengadam N, Chandrasekhara V, Kochman ML, Ginsberg GG, et al. Comparing American Gastroenterological Association Pancreatic Cyst Management Guidelines with Fukuoka Consensus Guidelines as Predictors of Advanced Neoplasia in Patients with Suspected Pancreatic Cystic Neoplasms. J Am Coll Surg. 2016;223:729–37.e1.
pubmed: 27497827
Del Chiaro M, Verbeke C, Salvia R, Klöppel G, Werner J, McKay C, et al. European experts consensus statement on cystic tumours of the pancreas. Dig Liver Dis. 2013;45:703–11.
pubmed: 23415799
Vege SS, Ziring B, Jain R, Moayyedi P, Committee CG, Association AG. American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Gastroenterology. 2015;148:819–22; quize12–3.
pubmed: 25805375
Lekkerkerker SJ, Besselink MG, Busch OR, Verheij J, Engelbrecht MR, Rauws EA, et al. Comparing 3 guidelines on the management of surgically removed pancreatic cysts with regard to pathological outcome. Gastrointest Endosc. 2017;85:1025–31.
pubmed: 27693645
Farias GFA, Bernardo WM, De Moura DTH, Guedes HG, Brunaldi VO, Visconti TAC, et al. Endoscopic versus surgical treatment for pancreatic pseudocysts: Systematic review and meta-analysis. Medicine (Baltimore). 2019;98:e14255.
pmcid: 6407966
van der Waaij LA, van Dullemen HM, Porte RJ. Cyst fluid analysis in the differential diagnosis of pancreatic cystic lesions: a pooled analysis. Gastrointest Endosc. 2005;62:383–9.
pubmed: 16111956
Brugge WR, Lewandrowski K, Lee-Lewandrowski E, Centeno BA, Szydlo T, Regan S, et al. Diagnosis of pancreatic cystic neoplasms: a report of the cooperative pancreatic cyst study. Gastroenterology. 2004;126:1330–6.
pubmed: 15131794
Boot C. A review of pancreatic cyst fluid analysis in the differential diagnosis of pancreatic cyst lesions. Ann Clin Biochem. 2014;51:151–66.
pubmed: 24097809
Reid MD, Choi H, Balci S, Akkas G, Adsay V. Serous cystic neoplasms of the pancreas: clinicopathologic and molecular characteristics. Semin Diagn Pathol. 2014;31:475–83.
pubmed: 25441309
Wu J, Jiao Y, Dal Molin M, Maitra A, de Wilde RF, Wood LD, et al. Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A. 2011;108:21188–93.
pubmed: 22158988
pmcid: 3248495
Singhi AD, Nikiforova MN, Fasanella KE, McGrath KM, Pai RK, Ohori NP, et al. Preoperative GNAS and KRAS testing in the diagnosis of pancreatic mucinous cysts. Clin Cancer Res. 2014;20:4381–9.
pubmed: 24938521
Farrell JJ. Prevalence, Diagnosis and Management of Pancreatic Cystic Neoplasms: Current Status and Future Directions. Gut Liver. 2015;9:571–89.
pubmed: 26343068
pmcid: 4562774
Carr RA, Yip-Schneider MT, Dolejs S, Hancock BA, Wu H, Radovich M, et al. Pancreatic Cyst Fluid Vascular Endothelial Growth Factor A and Carcinoembryonic Antigen: A Highly Accurate Test for the Diagnosis of Serous Cystic Neoplasm. J Am Coll Surg. 2017.
Lee LS, Szafranska-Schwarzbach AE, Wylie D, Doyle LA, Bellizzi AM, Kadiyala V, et al. Investigating MicroRNA Expression Profiles in Pancreatic Cystic Neoplasms. Clin Transl Gastroenterol. 2014;5:e47.
pubmed: 24476997
pmcid: 3912316
Yip-Schneider MT, Wu H, Dumas RP, Hancock BA, Agaram N, Radovich M, et al. Vascular endothelial growth factor, a novel and highly accurate pancreatic fluid biomarker for serous pancreatic cysts. J Am Coll Surg. 2014;218:608–17.
pubmed: 24491241
Kosmahl M, Wagner J, Peters K, Sipos B, Klöppel G. Serous cystic neoplasms of the pancreas: an immunohistochemical analysis revealing alpha-inhibin, neuron-specific enolase, and MUC6 as new markers. Am J Surg Pathol. 2004;28:339–46.
pubmed: 15104296
Gbormittah FO, Haab BB, Partyka K, Garcia-Ott C, Hancapie M, Hancock WS. Characterization of glycoproteins in pancreatic cyst fluid using a high-performance multiple lectin affinity chromatography platform. J Proteome Res. 2014;13:289–99.
pubmed: 24303806
Park WG, Wu M, Bowen R, Zheng M, Fitch WL, Pai RK, et al. Metabolomic-derived novel cyst fluid biomarkers for pancreatic cysts: glucose and kynurenine. Gastrointest Endosc. 2013;78:295–302.e2.
pubmed: 23566642
pmcid: 3780566
Zikos T, Pham K, Bowen R, Chen AM, Banerjee S, Friedland S, et al. Cyst Fluid Glucose is Rapidly Feasible and Accurate in Diagnosing Mucinous Pancreatic Cysts. Am J Gastroenterol. 2015;110:909–14.
pubmed: 25986360
Tang LH, Aydin H, Brennan MF, Klimstra DS. Clinically aggressive solid pseudopapillary tumors of the pancreas: a report of two cases with components of undifferentiated carcinoma and a comparative clinicopathologic analysis of 34 conventional cases. Am J Surg Pathol. 2005;29:512–9.
pubmed: 15767807
Kim MJ, Jang SJ, Yu E. Loss of E-cadherin and cytoplasmic-nuclear expression of beta-catenin are the most useful immunoprofiles in the diagnosis of solid-pseudopapillary neoplasm of the pancreas. Hum Pathol. 2008;39:251–8.
pubmed: 17959228
Springer S, Wang Y, Dal Molin M, Masica DL, Jiao Y, Kinde I, et al. A combination of molecular markers and clinical features improve the classification of pancreatic cysts. Gastroenterology. 2015;149:1501–10.
pubmed: 26253305
pmcid: 4782782
Park M, Kim M, Hwang D, Kim WK, Kim SK, Shin J, et al. Characterization of gene expression and activated signaling pathways in solid-pseudopapillary neoplasm of pancreas. Mod Pathol. 2014;27:580–93.
pubmed: 24072181
Li P, Hu Y, Yi J, Li J, Yang J, Wang J. Identification of potential biomarkers to differentially diagnose solid pseudopapillary tumors and pancreatic malignancies via a gene regulatory network. J Transl Med. 2015;13:361.
pubmed: 26578390
pmcid: 4650856
Kim EK, Jang M, Park M, Kim H. LEF1, TFE3, and AR are putative diagnostic markers of solid pseudopapillary neoplasms. Oncotarget. 2017;8:93404–13.
pubmed: 29212159
pmcid: 5706805
Harrison G, Hemmerich A, Guy C, Perkinson K, Fleming D, McCall S, et al. Overexpression of SOX11 and TFE3 in Solid-Pseudopapillary Neoplasms of the Pancreas. Am J Clin Pathol. 2017;149:67–75.
pubmed: 29272888
Foo WC, Harrison G, Zhang X. Immunocytochemistry for SOX-11 and TFE3 as diagnostic markers for solid pseudopapillary neoplasms of the pancreas in FNA biopsies. Cancer Cytopathol. 2017;125:831–7.
pubmed: 29045075
Park M, Lim JS, Lee HJ, Na K, Lee MJ, Kang CM, et al. Distinct Protein Expression Profiles of Solid-Pseudopapillary Neoplasms of the Pancreas. J Proteome Res. 2015;14:3007–14.
pubmed: 26148796
Zhu Y, Xu H, Chen H, Xie J, Shi M, Shen B, et al. Proteomic analysis of solid pseudopapillary tumor of the pancreas reveals dysfunction of the endoplasmic reticulum protein processing pathway. Mol Cell Proteomics. 2014;13:2593–603.
pubmed: 24997997
pmcid: 4188989
Ghosh R, Mallik SR, Mathur SR, Iyer VK. CD 99 immunocytochemistry in solid pseudopapillary tumor of pancreas: A study on fine-needle aspiration cytology smears. J Cytol. 2013;30:151–5.
pubmed: 24130404
pmcid: 3793349
Shen Y, Wang Z, Zhu J, Chen Y, Gu W, Liu Q. α-Methylacyl-CoA racemase (P504S) is a useful marker for the differential diagnosis of solid pseudopapillary neoplasm of the pancreas. Ann Diagn Pathol. 2014;18:146–50.
pubmed: 24675392
Guo X, Zhan X, Li Z. Molecular Analyses of Aspirated Cystic Fluid for the Differential Diagnosis of Cystic Lesions of the Pancreas: A Systematic Review and Meta-Analysis. Gastroenterol Res Pract. 2016;2016:3546085.
pubmed: 26819604
Gillis A, Cipollone I, Cousins G, Conlon K. Does EUS-FNA molecular analysis carry additional value when compared to cytology in the diagnosis of pancreatic cystic neoplasm? A systematic review. HPB (Oxford). 2015;17:377–86.
Matthaei H, Wylie D, Lloyd MB, Dal Molin M, Kemppainen J, Mayo SC, et al. miRNA biomarkers in cyst fluid augment the diagnosis and management of pancreatic cysts. Clin Cancer Res. 2012;18:4713–24.
pubmed: 22723372
pmcid: 3547600
Utomo WK, Looijenga LH, Bruno MJ, Hansen BE, Gillis A, Biermann K, et al. A MicroRNA Panel in Pancreatic Cyst Fluid for the Risk Stratification of Pancreatic Cysts in a Prospective Cohort. Mol Ther Nucleic Acids. 2016;5:e350.
pubmed: 28131248
pmcid: 5023405
Ryu JK, Matthaei H, Dal Molin M, Hong SM, Canto MI, Schulick RD, et al. Elevated microRNA miR-21 levels in pancreatic cyst fluid are predictive of mucinous precursor lesions of ductal adenocarcinoma. Pancreatology. 2011;11:343–50.
pubmed: 21757972
pmcid: 3142103
Farrell JJ, Toste P, Wu N, Li L, Wong J, Malkhassian D, et al. Endoscopically acquired pancreatic cyst fluid microRNA 21 and 221 are associated with invasive cancer. Am J Gastroenterol. 2013;108:1352–9.
pubmed: 23752880
Wang J, Paris PL, Chen J, Ngo V, Yao H, Frazier ML, et al. Next generation sequencing of pancreatic cyst fluid microRNAs from low grade-benign and high grade-invasive lesions. Cancer Lett. 2015;356:404–9.
pubmed: 25304377
Henry JC, Bassi C, Giovinazzo F, Bloomston M. MicroRNA from pancreatic duct aspirate differentiates cystic lesions of the pancreas. Ann Surg Oncol. 2013;20 Suppl 3:S661–6.
pubmed: 23884752
Park J, Yun HS, Lee KH, Lee KT, Lee JK, Lee SY. Discovery and Validation of Biomarkers That Distinguish Mucinous and Nonmucinous Pancreatic Cysts. Cancer Res. 2015;75:3227–35.
pubmed: 26122842
Räty S, Sand J, Laukkarinen J, Vasama K, Bassi C, Salvia R, et al. Cyst fluid SPINK1 may help to differentiate benign and potentially malignant cystic pancreatic lesions. Pancreatology. 2013;13:530–3.
pubmed: 24075519
Ivry SL, Sharib JM, Dominguez DA, Roy N, Hatcher SE, Yip-Schneider MT, et al. Global Protease Activity Profiling Provides Differential Diagnosis of Pancreatic Cysts. Clin Cancer Res. 2017;23:4865–74.
pubmed: 28424202
pmcid: 5712228
Hammel PR, Forgue-Lafitte ME, Lévy P, Voitot H, Vilgrain V, Fléjou JF, et al. Detection of gastric mucins (M1 antigens) in cyst fluid for the diagnosis of cystic lesions of the pancreas. Int J Cancer. 1997;74:286–90.
pubmed: 9221806
Sinha J, Cao Z, Dai J, Tang H, Partyka K, Hostetter G, et al. A Gastric Glycoform of MUC5AC Is a Biomarker of Mucinous Cysts of the Pancreas. PLoS One. 2016;11:e0167070.
pubmed: 27992432
pmcid: 5167232
Haab BB, Porter A, Yue T, Li L, Scheiman J, Anderson MA, et al. Glycosylation variants of mucins and CEACAMs as candidate biomarkers for the diagnosis of pancreatic cystic neoplasms. Ann Surg. 2010;251:937–45.
pubmed: 20395854
pmcid: 3713623
Jabbar KS, Arike L, Verbeke CS, Sadik R, Hansson GC. Highly Accurate Identification of Cystic Precursor Lesions of Pancreatic Cancer Through Targeted Mass Spectrometry: A Phase IIc Diagnostic Study. J Clin Oncol. 2018;36:367–75.
pubmed: 29166170
Lüttges J, Feyerabend B, Buchelt T, Pacena M, Klöppel G. The mucin profile of noninvasive and invasive mucinous cystic neoplasms of the pancreas. Am J Surg Pathol. 2002;26:466–71.
pubmed: 11914624
Lee JH, Kim Y, Choi JW, Kim YS. KRAS, GNAS, and RNF43 mutations in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis. Springerplus. 2016;5:1172.
pubmed: 27512631
pmcid: 4960083
Jimenez RE, Warshaw AL, Z'graggen K, Hartwig W, Taylor DZ, Compton CC, et al. Sequential accumulation of K-ras mutations and p53 overexpression in the progression of pancreatic mucinous cystic neoplasms to malignancy. Ann Surg. 1999;230:501–9; discussion 9-11.
pubmed: 10522720
pmcid: 1420899
Iacobuzio-Donahue CA, Wilentz RE, Argani P, Yeo CJ, Cameron JL, Kern SE, et al. Dpc4 protein in mucinous cystic neoplasms of the pancreas: frequent loss of expression in invasive carcinomas suggests a role in genetic progression. Am J Surg Pathol. 2000;24:1544–8.
pubmed: 11075857
Terada T, Ohta T, Sasaki M, Nakanuma Y, Kim YS. Expression of MUC apomucins in normal pancreas and pancreatic tumours. J Pathol. 1996;180:160–5.
pubmed: 8976874
Basturk O, Khayyata S, Klimstra DS, Hruban RH, Zamboni G, Coban I, et al. Preferential expression of MUC6 in oncocytic and pancreatobiliary types of intraductal papillary neoplasms highlights a pyloropancreatic pathway, distinct from the intestinal pathway, in pancreatic carcinogenesis. Am J Surg Pathol. 2010;34:364–70.
pubmed: 20139757
pmcid: 3160822
Paini M, Crippa S, Partelli S, Scopelliti F, Tamburrino D, Baldoni A, et al. Molecular pathology of intraductal papillary mucinous neoplasms of the pancreas. World J Gastroenterol. 2014;20:10008–23.
pubmed: 25110429
pmcid: 4123331
Kallen ME, Naini BV. Intraductal Oncocytic Papillary Neoplasms of the Pancreas. Archives of Pathology & Laboratory Medicine. 2016;140:992–6.
Qi X, Zhao X, Su J, Xu M, Zhang W, Sheng H, et al. Malignant transformation and overall survival of morphological subtypes of intraductal papillary mucinous neoplasms of the pancreas: A network meta-analysis. European Journal of Internal Medicine. 2015;26:652–7.
pubmed: 26275457
Furukawa T, Hatori T, Fujita I, Yamamoto M, Kobayashi M, Ohike N, et al. Prognostic relevance of morphological types of intraductal papillary mucinous neoplasms of the pancreas. Gut. 2011;60:509–16.
pubmed: 21193453
Siddiqui AA, Kowalski TE, Kedika R, Roy A, Loren DE, Ellsworth E, et al. EUS-guided pancreatic fluid aspiration for DNA analysis of KRAS and GNAS mutations for the evaluation of pancreatic cystic neoplasia: a pilot study. Gastrointest Endosc. 2013;77:669–70.
pubmed: 23498145
Nissim S, Idos GE, Wu B. Genetic markers of malignant transformation in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis. Pancreas. 2012;41:1195–205.
pubmed: 22750975
pmcid: 4850028
Bournet B, Vignolle-Vidoni A, Grand D, Roques C, Breibach F, Cros J, et al. Endoscopic ultrasound-guided fine-needle aspiration plus KRAS and GNAS mutation in malignant intraductal papillary mucinous neoplasm of the pancreas. Endosc Int Open. 2016;4:E1228-E35.
pubmed: 27995180
pmcid: 5161125
Kadayifci A, Atar M, Wang JL, Forcione DG, Casey BW, Pitman MB, et al. Value of adding GNAS testing to pancreatic cyst fluid KRAS and carcinoembryonic antigen analysis for the diagnosis of intraductal papillary mucinous neoplasms. Dig Endosc. 2017;29:111–7.
pubmed: 27514845
Takano S, Fukasawa M, Kadokura M, Shindo H, Takahashi E, Hirose S, et al. Next-Generation Sequencing Revealed TP53 Mutations to Be Malignant Marker for Intraductal Papillary Mucinous Neoplasms That Could Be Detected Using Pancreatic Juice. Pancreas. 2017;46:1281–7.
pubmed: 28930868
Kuboki Y, Shimizu K, Hatori T, Yamamoto M, Shibata N, Shiratori K, et al. Molecular biomarkers for progression of intraductal papillary mucinous neoplasm of the pancreas. Pancreas. 2015;44:227–35.
pubmed: 25423558
Wada K. p16 and p53 gene alterations and accumulations in the malignant evolution of intraductal papillary-mucinous tumors of the pancreas. J Hepatobiliary Pancreat Surg. 2002;9:76–85.
pubmed: 12021900
Rosenbaum MW, Jones M, Dudley JC, Le LP, Iafrate AJ, Pitman MB. Next-generation sequencing adds value to the preoperative diagnosis of pancreatic cysts. Cancer Cytopathol. 2017;125:41–7.
pubmed: 27647802
Singhi AD, McGrath K, Brand RE, Khalid A, Zeh HJ, Chennat JS, et al. Preoperative next-generation sequencing of pancreatic cyst fluid is highly accurate in cyst classification and detection of advanced neoplasia. Gut. 2018;67:2131–41.
pubmed: 28970292
Tan MC, Basturk O, Brannon AR, Bhanot U, Scott SN, Bouvier N, et al. GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma. J Am Coll Surg. 2015;220:845–54.e1.
pubmed: 25840541
pmcid: 4409519
Komatsu H, Tanji E, Sakata N, Aoki T, Motoi F, Naitoh T, et al. A GNAS mutation found in pancreatic intraductal papillary mucinous neoplasms induces drastic alterations of gene expression profiles with upregulation of mucin genes. PLoS One. 2014;9:e87875.
pubmed: 24498386
pmcid: 3912139
Hashimoto Y, Murakami Y, Uemura K, Hayashidani Y, Sudo T, Ohge H, et al. Telomere shortening and telomerase expression during multistage carcinogenesis of intraductal papillary mucinous neoplasms of the pancreas. J Gastrointest Surg. 2008;12:17–28; discussion −9.
pubmed: 17960465
Jang KT, Lee KT, Lee JG, Choi SH, Heo JS, Choi DW, et al. Immunohistochemical expression of Sonic hedgehog in intraductal papillary mucinous tumor of the pancreas. Appl Immunohistochem Mol Morphol. 2007;15:294–8.
pubmed: 17721274
Islam HK, Fujioka Y, Tomidokoro T, Sugiura H, Takahashi T, Kondo S, et al. Immunohistochemical analysis of expression of molecular biologic factors in intraductal papillary-mucinous tumors of pancreas--diagnostic and biologic significance. Hepatogastroenterology. 1999;46:2599–605.
pubmed: 10522048
Hong SM, Omura N, Vincent A, Li A, Knight S, Yu J, et al. Genome-wide CpG island profiling of intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Res. 2012;18:700–12.
pubmed: 22173550
Hata T, Dal Molin M, Hong SM, Tamura K, Suenaga M, Yu J, et al. Predicting the Grade of Dysplasia of Pancreatic Cystic Neoplasms Using Cyst Fluid DNA Methylation Markers. Clin Cancer Res. 2017;23:3935–44.
pubmed: 28148542
pmcid: 5511555
Vila-Navarro E, Vila-Casadesús M, Moreira L, Duran-Sanchon S, Sinha R, Ginés À, et al. MicroRNAs for Detection of Pancreatic Neoplasia: Biomarker Discovery by Next-generation Sequencing and Validation in 2 Independent Cohorts. Ann Surg. 2017;265:1226–34.
pubmed: 27232245
Lubezky N, Loewenstein S, Ben-Haim M, Brazowski E, Marmor S, Pasmanik-Chor M, et al. MicroRNA expression signatures in intraductal papillary mucinous neoplasm of the pancreas. Surgery. 2013;153:663–72.
pubmed: 23305591
Permuth-Wey J, Chen YA, Fisher K, McCarthy S, Qu X, Lloyd MC, et al. A genome-wide investigation of microRNA expression identifies biologically-meaningful microRNAs that distinguish between high-risk and low-risk intraductal papillary mucinous neoplasms of the pancreas. PLoS One. 2015;10:e0116869.
pubmed: 25607660
pmcid: 4301643
Caponi S, Funel N, Frampton AE, Mosca F, Santarpia L, Van der Velde AG, et al. The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms. Ann Oncol. 2013;24:734–41.
pubmed: 23139258
Habbe N, Koorstra JB, Mendell JT, Offerhaus GJ, Ryu JK, Feldmann G, et al. MicroRNA miR-155 is a biomarker of early pancreatic neoplasia. Cancer Biol Ther. 2009;8:340–6.
pubmed: 19106647
pmcid: 2692997
Frampton AE, Gall TM, Giovannetti E, Stebbing J, Castellano L, Jiao LR, et al. Distinct miRNA profiles are associated with malignant transformation of pancreatic cystic tumors revealing potential biomarkers for clinical use. Expert Rev Mol Diagn. 2013;13:325–9.
pubmed: 23638815
Lahat G, Lubezky N, Loewenstein S, Nizri E, Gan S, Pasmanik-Chor M, et al. Epithelial-to-mesenchymal transition (EMT) in intraductal papillary mucinous neoplasm (IPMN) is associated with high tumor grade and adverse outcomes. Ann Surg Oncol. 2014;21 Suppl 4:S750–7.
pubmed: 25069861
Permuth-Wey J, Chen DT, Fulp WJ, Yoder SJ, Zhang Y, Georgeades C, et al. Plasma MicroRNAs as Novel Biomarkers for Patients with Intraductal Papillary Mucinous Neoplasms of the Pancreas. Cancer Prev Res (Phila). 2015;8:826–34.
pubmed: 26314797
pmcid: 4560649
Aso T, Ohtsuka T, Tamura K, Ideno N, Kono H, Nagayoshi Y, et al. Elevated expression level of microRNA-196a is predictive of intestinal-type intraductal papillary mucinous neoplasm of the pancreas. Pancreas. 2014;43:361–6.
pubmed: 24622064
Permuth JB, Choi J, Balarunathan Y, Kim J, Chen DT, Chen L, et al. Combining radiomic features with a miRNA classifier may improve prediction of malignant pathology for pancreatic intraductal papillary mucinous neoplasms. Oncotarget. 2016;7:85785–97.
pubmed: 27589689
pmcid: 5349874
Permuth JB, Chen DT, Yoder SJ, Li J, Smith AT, Choi JW, et al. Linc-ing Circulating Long Non-coding RNAs to the Diagnosis and Malignant Prediction of Intraductal Papillary Mucinous Neoplasms of the Pancreas. Sci Rep. 2017;7:10484.
pubmed: 28874676
pmcid: 5585319
Morimatsu K, Aishima S, Yamamoto H, Hayashi A, Nakata K, Oda Y, et al. Insulin-like growth factor II messenger RNA-binding protein-3 is a valuable diagnostic and prognostic marker of intraductal papillary mucinous neoplasm. Hum Pathol. 2013;44:1714–21.
pubmed: 23597774
Rebours V, Le Faouder J, Laouirem S, Mebarki M, Albuquerque M, Camadro JM, et al. In situ proteomic analysis by MALDI imaging identifies ubiquitin and thymosin-β4 as markers of malignant intraductal pancreatic mucinous neoplasms. Pancreatology. 2014;14:117–24.
pubmed: 24650966
Bausch D, Mino-Kenudson M, Fernández-Del Castillo C, Warshaw AL, Kelly KA, Thayer SP. Plectin-1 is a biomarker of malignant pancreatic intraductal papillary mucinous neoplasms. J Gastrointest Surg. 2009;13:1948–54; discussion 54.
pubmed: 19760374
pmcid: 3806105
Das KK, Xiao H, Geng X, Fernandez-Del-Castillo C, Morales-Oyarvide V, Daglilar E, et al. mAb Das-1 is specific for high-risk and malignant intraductal papillary mucinous neoplasm (IPMN). Gut. 2014;63:1626–34.
pubmed: 24277729
DiMaio CJ, Weis-Garcia F, Bagiella E, Tang LH, Allen PJ. Pancreatic cyst fluid concentration of high-mobility group A2 protein acts as a differential biomarker of dysplasia in intraductal papillary mucinous neoplasm. Gastrointest Endosc. 2016;83:1205–9.
pubmed: 26408423
Do M, Han D, Wang JI, Kim H, Kwon W, Han Y, et al. Quantitative proteomic analysis of pancreatic cyst fluid proteins associated with malignancy in intraductal papillary mucinous neoplasms. Clin Proteomics. 2018;15:17.
pubmed: 29713252
pmcid: 5907296
Hata T, Dal Molin M, Suenaga M, Yu J, Pittman M, Weiss M, et al. Cyst Fluid Telomerase Activity Predicts the Histologic Grade of Cystic Neoplasms of the Pancreas. Clin Cancer Res. 2016;22:5141–51.
pubmed: 27230749
pmcid: 5065739
Satoh K, Hamada S, Kanno A, Hirota M, Umino J, Ito H, et al. Expression of MSX2 predicts malignancy of branch duct intraductal papillary mucinous neoplasm of the pancreas. J Gastroenterol. 2010;45:763–70.
pubmed: 20107842
Kakizaki Y, Makino N, Tozawa T, Honda T, Matsuda A, Ikeda Y, et al. Stromal Fibrosis and Expression of Matricellular Proteins Correlate With Histological Grade of Intraductal Papillary Mucinous Neoplasm of the Pancreas. Pancreas. 2016;45:1145–52.
pubmed: 26967452
pmcid: 4993122
Terris B, Dubois S, Buisine MP, Sauvanet A, Ruszniewski P, Aubert JP, et al. Mucin gene expression in intraductal papillary-mucinous pancreatic tumours and related lesions. J Pathol. 2002;197:632–7.
pubmed: 12210083
Shimamoto T, Tani M, Kawai M, Hirono S, Ina S, Miyazawa M, et al. MUC1 is a useful molecular marker for malignant intraductal papillary mucinous neoplasms in pancreatic juice obtained from endoscopic retrograde pancreatography. Pancreas. 2010;39:879–83.
pubmed: 20357691
Matsumoto K, Takeda Y, Harada K, Onoyama T, Kawata S, Horie Y, et al. Clinical Impact of the KL-6 Concentration of Pancreatic Juice for Diagnosing Pancreatic Masses. Biomed Res Int. 2015;2015:528304.
pubmed: 26451373
pmcid: 4584219
Hara T, Ikebe D, Odaka A, Sudo K, Nakamura K, Yamamoto H, et al. Preoperative histological subtype classification of intraductal papillary mucinous neoplasms (IPMN) by pancreatic juice cytology with MUC stain. Ann Surg. 2013;257:1103–11.
pubmed: 23364699
Kanno A, Satoh K, Kimura K, Hirota M, Umino J, Masamune A, et al. The expression of MUC4 and MUC5AC is related to the biologic malignancy of intraductal papillary mucinous neoplasms of the pancreas. Pancreas. 2006;33:391–6.
pubmed: 17079945
Maker AV, Katabi N, Gonen M, DeMatteo RP, D'Angelica MI, Fong Y, et al. Pancreatic cyst fluid and serum mucin levels predict dysplasia in intraductal papillary mucinous neoplasms of the pancreas. Ann Surg Oncol. 2011;18:199–206.
pubmed: 20717734
Reid MD, Basturk O, Thirabanjasak D, Hruban RH, Klimstra DS, Bagci P, et al. Tumor-infiltrating neutrophils in pancreatic neoplasia. Mod Pathol. 2011;24:1612–9.
pubmed: 21822201
pmcid: 3227778
Sadot E, Basturk O, Klimstra DS, Gönen M, Lokshin A, Do RK, et al. Tumor-associated Neutrophils and Malignant Progression in Intraductal Papillary Mucinous Neoplasms: An Opportunity for Identification of High-risk Disease. Ann Surg. 2015;262:1102–7.
pubmed: 25563865
pmcid: 4643387
Al Efishat MA, Attiyeh MA, Eaton AA, Gönen M, Prosser D, Lokshin AE, et al. Multi-institutional Validation Study of Pancreatic Cyst Fluid Protein Analysis for Prediction of High-risk Intraductal Papillary Mucinous Neoplasms of the Pancreas. Ann Surg. 2018;268:340–7.
pubmed: 28700444
pmcid: 5764837
Maker AV, Katabi N, Qin LX, Klimstra DS, Schattner M, Brennan MF, et al. Cyst fluid interleukin-1beta (IL1beta) levels predict the risk of carcinoma in intraductal papillary mucinous neoplasms of the pancreas. Clin Cancer Res. 2011;17:1502–8.
pubmed: 21266527
pmcid: 3065716
Yip-Schneider MT, Carr RA, Wu H, Schmidt CM. Prostaglandin E. J Am Coll Surg. 2017;225:481–7.
pubmed: 28739154
pmcid: 5614873
Zhou W, Rong Y, Kuang T, Xu Y, Shen X, Ji Y, et al. The value of systemic inflammatory markers in identifying malignancy in mucinous pancreatic cystic neoplasms. Oncotarget. 2017;8:115561–9.
pubmed: 29383181
pmcid: 5777793
Gemenetzis G, Bagante F, Griffin JF, Rezaee N, Javed AA, Manos LL, et al. Neutrophil-to-lymphocyte Ratio is a Predictive Marker for Invasive Malignancy in Intraductal Papillary Mucinous Neoplasms of the Pancreas. Ann Surg. 2017;266:339–45.
pubmed: 27631774
Root A, Allen P, Tempst P, Yu K. Protein Biomarkers for Early Detection of Pancreatic Ductal Adenocarcinoma: Progress and Challenges. Cancers (Basel). 2018;10.
Nakamura M, Miyasaka Y, Sadakari Y, Date K, Ohtsuka T. Comparison of guidelines for intraductal papillary mucinous neoplasm: What is the next step beyond the current guidelines? Ann Gastroenterol Surg. 2017;1:90–8.
pubmed: 29863135
pmcid: 5881340